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BACKGROUND: Both statins and proprotein convertase subtilisin/
kexin type 9 (PCSK9) inhibitors lower blood low-density lipoprotein 
cholesterol levels to reduce risk of cardiovascular events. To assess 
potential differences between metabolic effects of these 2 lipid-lowering 
therapies, we performed detailed lipid and metabolite profiling of a large 
randomized statin trial and compared the results with the effects of 
genetic inhibition of PCSK9, acting as a naturally occurring trial.
METHODS: Two hundred twenty-eight circulating metabolic measures 
were quantified by nuclear magnetic resonance spectroscopy, including 
lipoprotein subclass concentrations and their lipid composition, fatty 
acids, and amino acids, for 5359 individuals (2659 on treatment) in the 
PROSPER (Prospective Study of Pravastatin in the Elderly at Risk) trial at 6 
months postrandomization. The corresponding metabolic measures were 
analyzed in 8 population cohorts (N=72 185) using PCSK9 rs11591147 
as an unconfounded proxy to mimic the therapeutic effects of PCSK9 
inhibitors.
RESULTS: Scaled to an equivalent lowering of low-density lipoprotein 
cholesterol, the effects of genetic inhibition of PCSK9 on 228 metabolic 
markers were generally consistent with those of statin therapy (R2=0.88). 
Alterations in lipoprotein lipid composition and fatty acid distribution 
were similar. However, discrepancies were observed for very-low-density 
lipoprotein lipid measures. For instance, genetic inhibition of PCSK9 had 
weaker effects on lowering of very-low-density lipoprotein cholesterol 
compared with statin therapy (54% versus 77% reduction, relative to 
the lowering effect on low-density lipoprotein cholesterol; P=2×10-7 for 
heterogeneity). Genetic inhibition of PCSK9 showed no significant effects 
on amino acids, ketones, or a marker of inflammation (GlycA), whereas 
statin treatment weakly lowered GlycA levels.
CONCLUSIONS: Genetic inhibition of PCSK9 had similar metabolic effects 
to statin therapy on detailed lipid and metabolite profiles. However, 
PCSK9 inhibitors are predicted to have weaker effects on very-low-density 
lipoprotein lipids compared with statins for an equivalent lowering of 
low-density lipoprotein cholesterol, which potentially translate into smaller 
reductions in cardiovascular disease risk.
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Statins are first line therapy to lower blood levels of low-density lipoprotein cholesterol (LDL-C) and reduce the risk of cardiovascular events.1–3 Treat-
ment with proprotein convertase subtilisin/kexin type 9 
(PCSK9) inhibitors has emerged as an additional effective 
therapy to lower LDL-C, resulting in reductions of ≈45% 
to 60%.4,5 Large cardiovascular outcome trials have re-
cently demonstrated that PCSK9 inhibitors reduce the 
risk of major cardiovascular events when added to statin 
treatment.6,7 Based on the first major outcome trials,6,7 
there has been some suggestions that PCSK9 inhibitors 
may be slightly less efficacious than statins for equivalent 
LDL-C reductions; however, other reports suggest that 
this is not the case, with apparent differences in cardio-
vascular event reduction explained by the short duration 
of the PCSK9 trials.8 Assessment of the detailed lipopro-
tein and other metabolic effects of statins and PCSK9 
inhibitors could provide a more detailed understanding 
of these lipid-lowering therapies and shed light on po-
tential differential effects on lipid metabolism.
The anticipated pharmacological effects of PCSK9 
inhibitors may be assessed by LDL-C lowering alleles in 
the PCSK9 gene, which act as unconfounded proxies 
for the lifetime effects of treatments.9–11 The observa-
tion of a prominent lower risk of coronary heart disease 
with LDL-C–lowering alleles in PCSK9 was pivotal for 
accelerating the development of anti-PCSK9 therapeu-
tics.10 Supporting the validity of using genetic proxies 
for molecular characterization of lipid-lowering targets, 
we have previously shown that LDL-C–lowering alleles 
in HMGCR (the gene encoding the target for statins) 
closely recapitulate the detailed metabolic changes as-
sociated with starting statin therapy in longitudinal co-
horts, as assessed by nuclear magnetic resonance (NMR) 
metabolomics.12 These detailed metabolic effects of 
statins were recently confirmed in PREVEND IT (Preven-
tion of Renal and Vascular End-stage Disease Interven-
tion Trial), a small randomized trial.13 Other studies have 
assessed the associations of PCSK9 variants with lipo-
protein subclass profiles,14,15 and the treatment effects 
of PCSK9 inhibitors on lipoprotein particle concentra-
tions and lipidomic measures have been examined in 
several small trials.16–18 However, prior studies have had 
limited power to assess potential differences between 
PCSK9 inhibition and statin therapy for equivalent re-
ductions in LDL-C, complicating direct comparisons of 
their impact on detailed lipid and metabolite measures.
In the present study, we examined the effects of 
statin therapy and genetic inhibition of PCSK9 on a 
circulating profile of 228 metabolic measures, quanti-
fied by NMR metabolomics, including lipoprotein sub-
classes, their lipid concentrations and composition, 
fatty acid balance, and several nonlipid pathways. The 
metabolic effects of statin treatment were assessed in 
a large randomized, placebo-controlled trial. In the ab-
sence of NMR metabolomics data from a large random-
ized trial of PCSK9 inhibitor therapy, the anticipated 
pharmacological effects were examined for a loss-of-
function variant in the PCSK9 gene.10,19 Comparing the 
metabolomic effects of genetic inhibition of PCSK9 to 
statin therapy provides an opportunity to examine pos-
sible discrepancies in many circulating biomarkers, and 
in turn elucidate potential therapeutic differences in the 
molecular mechanisms to reduce cardiovascular risk.
METHODS
The authors declare that the summary statistics are available 
within the article and its online-only Data Supplement. The 
individual patient data analyzed in this study are available by 
application to the respective cohort committees.
Study Design
An overview of the study design is shown in Figure 1. NMR 
metabolomics was performed on 5359 blood samples 
from the PROSPER (Prospective Study of Pravastatin in the 
Elderly at Risk) trial20 at 6-month postrandomization, and 
Clinical Perspective
What Is New?
• Detailed lipoprotein lipid and metabolic effects of 
statin therapy in a large randomized, controlled trial 
are compared with the corresponding effects of pro-
protein convertase subtilisin/kexin type 9 (PCSK9) 
genetic inhibition in large population studies, acting 
as a naturally occurring trial of PCSK9 inhibitors.
• We demonstrate generally consistent effects of statins 
and PCSK9 genetic inhibition on a wide range of lipid-
related metabolic markers when scaled to a similar 
lowering of low-density lipoprotein cholesterol.
• Differences are observed in lowering of very-low-
density lipoprotein lipids and, more subtly, for the 
inflammation marker GlycA, with PCSK9 inhibition 
appearing to have a weaker effect in comparison 
with statins.
What Are the Clinical Implications?
• If very-low-density lipoprotein lipids have inde-
pendent causal effects on cardiovascular disease 
risk, the observed discrepancy on very-low-density 
lipoprotein lipid lowering could contribute to dif-
ferences in cardiovascular risk reductions between 
statins and PCSK9 inhibitors for an equivalent 
reduction in low-density lipoprotein cholesterol.
• The null associations on glycolysis-related measures 
and amino acids suggests that alternative mecha-
nisms account for the association of genetic vari-
ants in PCSK9 and risk of type 2 diabetes mellitus.
• These results exemplify the utility of large-scale 
metabolomic profiling with genetics and random-
ized trial data to uncover potential molecular differ-
ences between related therapeutics.
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72 185 samples from eight population cohorts from the 
United Kingdom (INTERVAL,21 ALSPAC [Avon Longitudinal 
Study of Parents] mothers and offspring22,23), Finland 
(FINRISK-1997, FINRISK-2007, and Northern Finland Birth 
Cohort studies 1966 and 198624–26), and China (China 
Kadoorie Biobank27). All study participants provided writ-
ten informed consent, and study protocols were approved 
by the local ethics committees.
PROSPER is a double-blind, randomized, placebo-con-
trolled trial investigating the benefit of pravastatin (40 mg/d) 
in elderly individuals at risk of cardiovascular disease, with 
5804 participants (70–82 years old) from Scotland, Ireland, 
and The Netherlands enrolled between December 1997 and 
May 1999.28 All participants had above average plasma total 
cholesterol concentration (4.0–9.0 mmol/L) at baseline, and 
50% had prior vascular disease. For the present study, 5359 
Figure 1. Overview of the study design and 
statistical analyses.
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samples (2659 on pravastatin) were measured by NMR metab-
olomics; all were previously unthawed 6-month postrandom-
ization EDTA plasma samples stored at −80°C.28 Metabolite 
data from baseline samples were not available, however the 
randomization should ensure that there are limited between-
group differences at baseline. Replication of the metabolic 
effects of pravastatin in PROSPER was done by comparison 
with recent results from PREVEND-IT.13
The metabolic effects of PCSK9 inhibition were assessed via 
the principle of Mendelian randomization using rs11591147-
T (R46L), a loss-of-function allele robustly associated with 
lower LDL-C and decreased cardiovascular risk.10,11 The fre-
quency of carriers of this effect allele was 2.2% (N=3135 
carriers); clinical characteristics of these individuals are speci-
fied in Table I in the online-only Data Supplement. Additional 
genetic variants in the PCSK9 locus, which have previously 
been used in Mendelian randomization studies on PCSK9,11,29 
and display low linkage disequilibrium with rs11591147 
(R2<0.2), were assessed in sensitivity analyses. To comple-
ment the comparison of PCSK9 rs11591147-T effects against 
the statin trial, we further examined the metabolic effects of 
rs12916-T in HMGCR in the same study population, acting as 
a pseudotrial of a very small statin dose by naturally occur-
ring randomization of HMG-CoA (HMG-coenzyme A) reduc-
tase inhibition.12,30 Among single nucleotide polymorphisms 
in HMGCR, rs12916 exhibits the strongest association with 
LDL-C and has been shown to affect hepatic HMGCR expres-
sion as well as cardiovascular risk.11,12,30 Last, to corroborate 
the validity of using genetic proxies to mimic the randomized 
trial effects, we compared metabolic effects of statin treat-
ment in PROSPER with the corresponding effects of HMGCR 
rs12916-T. Pregnant women and individuals on lipid-lowering 
treatment were excluded from the analyses where informa-
tion was available. Details of the cohorts are provided in 
Methods and Table I in the online-only Data Supplement.
Lipid and Metabolite Quantification
High-throughput NMR metabolomics was used to quantify 
228 lipoprotein lipids and polar metabolite measures from 
serum or plasma samples in the PROSPER trial and eight 
cohorts by the Nightingale platform (Nightingale Health Ltd, 
Helsinki, Finland). This provides simultaneous quantifica-
tion of routine lipids, particle concentration, and lipid com-
position of 14 lipoprotein subclasses, abundant fatty acids, 
amino acids, ketones, and glycolysis-related metabolites in 
absolute concentration units (Table II in the online-only Data 
Supplement).31 The Nightingale NMR metabolomics platform 
has been widely used in epidemiological studies,12,32,33 and the 
measurement method has been previously described.31–35
Statistical Analyses
The effects of statin therapy on the 228 metabolic measures 
in the PROSPER trial were assessed by comparing the mean 
metabolite concentrations in the treatment group with the 
placebo group at 6 months after randomization. The between-
group difference in concentrations for each metabolic mea-
sure was quantified separately using linear regression with 
metabolite concentration as outcome and treatment status 
as predictor, adjusted for age and sex. All metabolite concen-
trations were scaled to standard deviation (SD) units before 
assessing the differences, to enable comparison of measures 
with different units and across wide ranges of concentration 
levels. Results in absolute units are presented in Table III in 
the online-only Data Supplement. The percentage differences 
in metabolite concentrations, relative to the placebo group, 
were examined as secondary analyses.
The effect of genetic inhibition of PCSK9 on each of the 
228 metabolic measures was analyzed separately by fitting lin-
ear regression models with metabolite concentrations as out-
come and rs11591147-T allele count as predictor, representing 
the number of LDL-C lowering alleles. For sensitivity analysis, 
we conducted equivalent tests of each metabolic measure 
with rs12916-T in HMGCR as the predictor. All genetic analy-
ses assumed an additive effect and were adjusted for age, sex, 
and the first four genomic principal components. Effect sizes 
and standard errors from each cohort were combined using 
inverse variance-weighted fixed effect meta-analysis. All effect 
sizes were scaled to SD units of metabolite concentrations, 
as for analyses of PROSPER. The similarity between the over-
all patterns of metabolic effects attributable to PCSK9 inhibi-
tion and statin therapy was summarized using the linear fit of 
the effect estimates of 153 metabolic measures,12 covering all 
assayed measures except lipoprotein lipid ratios and 5 polar 
metabolites that could not be reliably quantified in PROSPER.
To facilitate comparison between the substantial metabolic 
effects of statin therapy with the smaller effects from genetic 
inhibition of PCSK9, results are presented relative to an equiv-
alent (1-SD) lowering of LDL-C within each study design (as 
quantified by NMR metabolomics).12,35 For the statin trial, the 
estimates derived from comparing statin treatment with pla-
cebo were divided by 1.19 (because statins lowered LDL-C 
by 1.19 SD); for PCSK9 genetic associations, per-allele effect 
estimates were divided by 0.44; for sensitivity analyses using 
rs12916 in HMGCR, per-allele effect estimates were divided 
by 0.078. The scaling relative to LDL-C was used to interpret 
the reported effect sizes as a change in concentration in each 
metabolic measure (in SD units) that accompanies a 1-SD 
lowering of LDL-C by statin therapy and genetic inhibition of 
PCSK9. This scaling is in line with the principles of Mendelian 
randomization assuming that the genetic variants in PCSK9 
and HMGCR serve as instruments for the LDL-C exposure.
Although 228 metabolic measures in total were examined, 
the number of independent tests performed is lower because 
of the correlated nature of the measures.35 The number of 
independent tests was estimated by taking the number of 
principal components explaining 99% of the variation in the 
metabolic measures.36 Thus, significance was considered at 
P<0.0003 to account for the testing of 54 independent meta-
bolic measures and 3 sets of analyses conducted (main effects 
of statins, PCSK9, and differences in their effects). The signifi-
cance of differences in the effect estimates was determined 
using the formula below, and the corresponding P values 
were derived from the normal distribution:
Z beta beta se sediff statin PCSK statin PCSK= −( ) −( )9 2 92
To facilitate visualization of the results, we focused on 
148 measures that cover all the metabolic pathways assayed; 
results for the remaining measures are shown in Figure I in 
the online-only Data Supplement and Tables IV through VI 
in the online-only Data Supplement. Statistical analyses were 
conducted using R3.2 (www.r-project.org).
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RESULTS
Figure 1 provides an overview of the study design. Char-
acteristics of the study populations are shown in the Ta-
ble. Characteristics of each of the eight cohorts used for 
the genetic analyses (N=72 185) are provided separately 
in Table I in the online-only Data Supplement. The meta-
bolic effects of statin treatment in PROSPER (pravastatin 
40 mg/daily) and genetic inhibition of PCSK9 are com-
pared in Figure 2. Overall, there was a high concordance 
of association of statin treatment and genetic inhibition 
of PCSK9 across the detailed metabolic profile (R2=0.88). 
Nonetheless, some discrepancies in effect sizes between 
statin treatment and PCSK9 rs11591147 were evident, 
primarily for very-low-density lipoprotein (VLDL) lipids.
Effects on Lipoprotein Lipids
The specific effects of statin therapy and genetic inhi-
bition of PCSK9 on lipid fractions and 14 lipoprotein 
subclasses are shown in Figure 3. Scaled to the same 
lowering of LDL-C, PCSK9 rs11591147 displayed sim-
ilar effects as statin therapy for total cholesterol and 
intermediate-density lipoprotein cholesterol, with no 
effect on high-density lipoprotein cholesterol. How-
ever, PCSK9 rs11591147 had a weaker effect on low-
ering VLDL cholesterol compared with statins (54% 
versus 77%, relative to the lowering effect on LDL-C 
[%LDL-C]; Phet=2×10
-7). These results were substantiat-
ed by the pattern of reduction in lipoprotein subclass 
particles: although the effects were similar for lower-
ing particle concentrations in all 3 (small, medium, 
and large) LDL subclasses, the extent of lowering of 
small, medium-sized, and large VLDL particle con-
centrations was smaller for PCSK9 rs11591147 com-
pared with statin therapy. A similar discrepancy was 
observed for cholesterol concentrations within the 6 
VLDL subclasses (Figure 4).
Both for statin therapy and genetic inhibition of 
PCSK9, the effects on triglyceride measures were mod-
est compared with those observed for cholesterol lev-
els in the same lipoprotein subfractions (Figure 3). The 
most pronounced lowering of triglycerides was seen for 
intermediate-density lipoprotein and LDL particles. For 
the equivalent reductions in LDL-C, PCSK9 rs11591147 
displayed a weaker effect than statin therapy on lower-
ing total plasma triglycerides (16%LDL-C versus 37%LDL-C; 
Phet=3×10
-6). Similar differences were seen for VLDL and 
high-density lipoprotein triglycerides. Consistent with 
the observed discrepancies for lowering of medium 
and large VLDL particles, genetic inhibition of PCSK9 
resulted in modestly larger VLDL size, whereas statin 
therapy had no effect on this measure. The effects on 
apolipoprotein concentrations were broadly similar, al-
beit a larger decrease was observed with statins for the 
ratio of apolipoprotein B to A-I.
Effects on Lipoprotein Composition
In addition to affecting the absolute lipid concentra-
tions, both statin therapy and genetic inhibition of 
PCSK9 had prominent effects on the relative abun-
dance of lipid types (free and esterified cholesterol, 
Table. Baseline Characteristics of Participants in the PROSPER Statin 
Trial and Cohorts for Analyses of Genetic Inhibition of PCSK9
Characteristics
PROSPER Statin Trial Cohorts in 
Analyses 
of Genetic 
Variants*Placebo Pravastatin
Number of individuals 2,700 2,659 72,185
Male, % 48.3 48.3 47.1
Age, y 75.3±3.4 75.4±3.3 39.3±5.3
Body mass index, kg/m2 26.8±4.3 26.8±4.1 25.2±4.4
Triglycerides, mmol/L 1.5±0.7 1.5±0.7 1.2±0.6
Total cholesterol, mmol/L 5.7±0.9 5.7±0.9 4.5±1.0
High-density lipoprotein 
cholesterol, mmol/L
1.3±0.3 1.3±0.4 1.4±0.4
Friedewald low-density 
lipoprotein cholesterol, mmol/L
3.8±0.8 3.8±0.8 2.4±0.8
Values are mean±SD. PROSPER indicates Prospective Study of Pravastatin in 
the Elderly at Risk.
*Pooled results of eight cohorts from different geographical and ethnic 
backgrounds and age distributions; characteristics of each cohort are detailed 
in Table I in the online-only Data Supplement. 
Figure 2. Consistency of metabolic effects of statin treatment and 
PCSK9 rs11591147-T. 
The effect size of each metabolic measure is given with 95% confidence inter-
vals in gray vertical and horizontal error bars. Color coding for the metabolic 
measure indicates the P value for heterogeneity between statin therapy and 
PCSK9 rs11591147-T. R2 = 0.880 indicates goodness of fit (correlation squared). 
The red dashed line denotes the linear fit for the consistency of the metabolic 
effects (slope of this line = 0.879). C indicates cholesterol; FA, fatty acids; FC, 
free cholesterol; HDL, high-density lipoprotein; IDL, intermediate-density lipopro-
tein; LDL, low-density lipoprotein; PL, phospholipids; PUFA, polyunsaturated 
fatty acids; TG, triglycerides; and VLDL, very-low-density lipoprotein. A full list of 
metabolite names is given in Table II in the online-only Data Supplement.
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triglycerides, and phospholipids) in differently sized li-
poprotein subclasses (Figure 4). The most pronounced 
lipoprotein composition effects were observed within 
LDL subclasses, with substantial lowering in the rela-
tive abundance of cholesteryl esters in LDL particles, 
alongside increases in the abundance of free cho-
lesterol and phospholipids. These effects were very 
similar for statin treatment compared with PCSK9 
rs11591147 for the equivalent reductions in LDL-C. 
Subtle discrepancies between statin and genetic inhi-
bition of PCSK9 were observed (eg, for the extent of 
lowering the fraction of free cholesterol in VLDL par-
ticles). The relative fraction of triglycerides in LDL and 
other apolipoprotein B–carrying particles increased 
similarly for both statins and PCSK9 rs11591147, 
whereas statin therapy caused larger decreases in the 
relative abundance of triglycerides within high-densi-
ty lipoproteins.
Figure 3. Effects of statin treatment and genetic inhibition of PCSK9 on lipoprotein and lipid levels. 
Differences in lipoprotein and lipid levels attributable to statin treatment were assessed in the PROSPER (Prospective Study of Pravastatin in the Elderly at Risk) trial at 6 
months post randomization (black diamonds; n=5359 for which 2659 were on pravastatin 40 mg/d). The corresponding effects of PCSK9 rs11591147-T were assessed 
for n=72 185 by meta-analysis of 8 cohorts (red circles). Error bars indicate 95% confidence intervals. Effect estimates are shown in SD-scaled concentration units 
(top axis) and relative to the lowering effect on low-density lipoprotein cholesterol (LDL-C; bottom axis). The results for different lipid types within the 14 lipoprotein 
subclasses are shown in Figure I in the online-only Data Supplement. Effects in absolute concentration units are listed in Table III in the online-only Data Supplement.
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Effects on Fatty Acids and Polar 
Metabolites
The effects of statin therapy and genetic inhibition of 
PCSK9 on fatty acid concentrations and the balance of 
fatty acid ratios are shown in Figure 5. Absolute concen-
trations of all fatty acids were lowered, with the most 
pronounced lowering for concentrations of linoleic acid, 
an omega-6 fatty acid commonly bound to cholesteryl 
esters in LDL particles. For the same lowering of LDL-
C, the effects of statins and PCSK9 rs11591147 were 
broadly similar, albeit with the lowering of total fatty 
acids being stronger in the case of statins (67%LDL-C ver-
sus 50%LDL-C; Phet=2×10
-4). The effects on the fatty acid 
ratios were generally modest, both for statin therapy 
and PCSK9 rs11591147. A pronounced discrepancy 
between these was observed for the overall degree of 
fatty acid unsaturation (16%LDL-C reduction for PCSK9 
versus 26%LDL-C increase for statin; Phet=4×10
-20).
We further assessed the effects of statin therapy 
and PCSK9 rs11591147 on polar metabolites and other 
metabolic measures quantified simultaneously in the 
metabolomics assay, including circulating amino ac-
ids, glycolysis metabolites, ketone bodies, and GlycA, 
a marker of chronic inflammation37 (Figure  6). Statin 
therapy caused only minor effects on these metabol-
ic measures; the strongest lowering effects were ob-
served for GlycA (17%LDL-C) and isoleucine (7%LDL-C). The 
effects of PCSK9 rs11591147 were also very close to 
null for these measures, including for glycolysis related 
metabolites and markers of insulin resistance. Of note, 
Figure 4. Effects of statin treatment and genetic inhibition of PCSK9 on lipoprotein composition. 
Differences in lipoprotein composition measures attributable to statin treatment were assessed 6 months post randomization in the PROSPER (Prospective Study of 
Pravastatin in the Elderly at Risk) trial (black). The corresponding effects of PCSK9 rs11591147-T were assessed for n=72 185 (red). Error bars indicate 95% confidence 
intervals. Results are shown in SD-scaled concentration units (top axis) and relative to the lowering effect on low-density lipoprotein cholesterol (LDL-C; bottom axis).
D
ow
nloaded from
 http://ahajournals.org by on December 11, 2018
Sliz et al Metabolomics of PCSK9 Inhibition and Statins
November 27, 2018 Circulation. 2018;138:2499–2512. DOI: 10.1161/CIRCULATIONAHA.118.0349422506
OR
IG
IN
AL
 R
ES
EA
RC
H 
AR
TI
CL
E
information on glucose, lactate, and pyruvate were not 
available in the PROSPER trial because of glycolysis pro-
gression after sample collection.
Comparison With PREVEND-IT Trial and 
Mendelian Randomization
To replicate the detailed metabolic effects of statins 
observed in PROSPER, we compared them with recent 
results from the PREVEND-IT trial obtained using the 
same NMR metabolomics platform.13 PREVEND-IT also 
examined the effects of pravastatin (40 mg/d) with me-
tabolomic changes assessed from baseline to 3 months 
for 195 individuals on treatment. The detailed meta-
bolic effects of statin treatment were highly concordant 
between PROSPER and PREVEND-IT (R2=0.96; Figure 
II in the online-only Data Supplement). When results 
were scaled to an equivalent lowering in LDL-C, 40 of 
44 significant discrepancies observed between effects 
of PCSK9 rs11591147 compared with PROSPER were 
similar or somewhat larger in PREVEND-IT, including 
the deviations in VLDL lipids; the only exceptions were 
4 measures of lipoprotein composition (fraction of free 
cholesterol in XXL-VLDL, triglyceride fraction in XL-VLDL, 
triglyceride fraction in L-HDL, and phospholipid fraction 
in S-LDL; Figure I in the online-only Data Supplement).
We further compared the metabolic effects of 
PCSK9 rs11591147 to those caused by rs12916 in the 
HMGCR gene, hereby using the genetic variants to ef-
fectively act as 2 naturally occurring trials in the same 
study population. The overall pattern of metabolic ef-
fects was highly similar for PCSK9 rs11591147 and 
HMGCR rs12916 (R2=0.92; Figure IIIA in the online-only 
Data Supplement). Nonetheless, scaled to the equiva-
lent LDL-C reductions, similar deviations were observed 
for VLDL lipids as when comparing PCSK9 rs11591147 
with the statin trial results (Figure IV in the online-only 
Data Supplement). Specifically, the lowering effect of 
HMGCR rs12916-T on particle concentrations of all 
VLDL subclasses was more similar to the effects of 
statin treatment than to those of PCSK9 rs11591147-
T, except in the case of very small VLDL. Differences 
were also observed for cholesterol and triglyceride con-
centrations in VLDL subclasses, whereas the lowering 
of total and saturated fatty acids was similar for the 
HMGCR and PCSK9 variants. However, power to detect 
statistical differences on individual measures was mod-
est, because of the much weaker LDL-C lowering effect 
of HMGCR rs12916. Last, the overall pattern of meta-
bolic effects of statin therapy in PROSPER was highly 
concordant to effects of HMGCR rs12916 (R2=0.95; 
Figure IIIB in the online-only Data Supplement), signi-
fying pharmacological and genetic inhibition of HMG-
CoA reductase, respectively.
In sensitivity analyses, the pattern of metabolic ef-
fects from PCSK9 rs11591147 was consistent across the 
cohorts (Figure V in the online-only Data Supplement). 
We also observed similar detailed patterns of metabolic 
Figure 5. Effects of statin treatment and genetic inhibition of PCSK9 on fatty acids. 
Differences in fatty acid levels attributable to statin treatment were assessed 6 months post randomization in the PROSPER (Prospective Study of Pravastatin in the 
Elderly at Risk) trial (black). The corresponding effects of PCSK9 rs11591147-T were assessed for n=72 185. Error bars indicate 95% confidence intervals. Results 
are shown in SD-scaled concentration units (top axis) and relative to the lowering effect on low-density lipoprotein cholesterol (LDL-C; bottom axis).
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effects as for rs11591147 when examining other ge-
netic variants in PCSK9 that have previously been used 
in Mendelian randomization studies11,29 (Figure VI in the 
online-only Data Supplement). Results for all the 228 
metabolic measures quantified are illustrated in Figures 
I and IV in the online-only Data Supplement. Metabolic 
effects in absolute concentration units are listed in Ta-
ble III in the online-only Data Supplement. The percent-
age differences in lipid and metabolite concentrations 
in the PROSPER statin trial are shown in Figure VII in 
the online-only Data Supplement. Effect estimates for 
all analyses are tabulated in Tables IV through VI in the 
online-only Data Supplement.
DISCUSSION
This study elucidates the comprehensive metabolic ef-
fects associated with statin therapy and PCSK9 inhibi-
tion. The results demonstrate that, in comparison with 
statin therapy, genetic inhibition of PCSK9 yields com-
parable changes across many different markers of lipid 
metabolism when scaled to the equivalent lowering of 
LDL-C. However, our results also suggest that PCSK9 
inhibitors may be somewhat less efficacious at lower-
ing VLDL particles. This could potentially contribute to 
subtle differences in potency for lowering cardiovas-
cular disease for the equivalent reductions in LDL-C,6 
because recent evidence suggests that VLDL cholesterol 
and other triglyceride-rich lipoprotein measures may 
causally contribute to the development of coronary 
heart disease independent of LDL-C.38–40 Moreover, trial 
data suggest that VLDL cholesterol is a stronger pre-
dictor of cardiovascular event risk than LDL-C among 
patients on statin therapy.41,42
Statins and PCSK9 inhibitors both lower circulating 
LDL-C levels via upregulation of LDL receptors on cell 
surfaces. Consistent with this shared mechanism for 
clearance of LDL particles, we found that statins and 
genetic inhibition of PCSK9 caused a highly consistent 
pattern of change across the detailed metabolic profile. 
Figure 6. Effects of statin treatment and genetic inhibition of PCSK9 on polar metabolites. 
Differences in metabolite levels due to statin treatment were assessed 6 months post randomization in the PROSPER (Prospective Study of Pravastatin in the Elderly 
at Risk) trial (black). The corresponding effects of PCSK9 rs11591147-T were assessed for n=72 185. Error bars indicate 95% confidence intervals. Glycine, glucose, 
lactate, pyruvate, and glycerol measures were not available from PROSPER. Results are shown in SD-scaled concentration units (top axis) and relative to the lower-
ing effect on low-density lipoprotein cholesterol (LDL-C; bottom axis).
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The metabolomic profiling of the PROSPER trial corrob-
orates previous studies with detailed measurements of 
metabolic effects of statin therapy, both as assessed in 
longitudinal cohorts and in a small randomized trial.12,13 
By profiling a large number of individuals from multiple 
cohorts, our results also validate and extend previous 
studies examining the detailed metabolic effects of 
PCSK9 rs11591147.14,15 Importantly, in relation to as-
sessment of potential side-effects of PCSK9 inhibition, 
we did not observe effects on amino acids or other non-
lipid metabolites, many of which are associated with 
risk of incident diabetes and cardiovascular events.32,43,44 
Our results on the pattern of lowering VLDL particles at-
tributable to genetic inhibition of PCSK9 are consistent 
with 2 small trials assessing the effects of the PCSK9 
inhibitors alirocumab and evolocumab on lipoprotein 
particle concentrations; both trials showed substantial 
reductions in small and medium-sized VLDL particles, 
whereas the particle concentration of the large VLDL 
fraction was not affected.16,17 Similar results were also 
found in a small PCSK9-inhibitor trial using separation 
of VLDL subfractions and other lipid measures by ul-
tracentrifugation, which also corroborate our results 
on a stronger effect on lowering of VLDL cholesterol 
in comparison with total plasma triglycerides.18 How-
ever, differences in assay methods complicate direct 
comparison of these trials to our results. Overall, these 
results provide orthogonal evidence for diverse lipopro-
tein lipid alterations by PCSK9 inhibitors, coherent with 
the comprehensive metabolic effects of statins.
Currently licensed PCSK9 inhibitors are given either 
instead of statins—when there is strong evidence of 
statin intolerance in those with familial hypercholester-
olemia—or in addition to maximally tolerated statins 
in patients with existing vascular disease.45 Such treat-
ment with PCSK9 inhibitors has been shown to be 
more efficacious in lowering LDL-C than the most po-
tent statins.4–6,8 Mendelian randomization studies com-
paring PCSK9 and HMGCR gene scores on cardiovascu-
lar outcomes have indicated nearly identical protective 
effects for equivalent reductions in LDL-C.11,46 However, 
when scaling the metabolic effects to an equivalent 
lowering in LDL-C, the results of the present study in-
dicate subtle differences on multiple lipoprotein lipid 
measures. The most notable discrepancy was for VLDL 
lipids, suggesting weaker potency of PCSK9 inhibitors 
in clearance of these triglyceride-rich lipoproteins as 
compared with statins. These findings are supported by 
a recent study providing evidence that statins, but not 
PCSK9 inhibitors, improve triglyceride-rich lipoprotein 
metabolism after an oral fat load in normolipidemic 
men.47 The causal consequences of these differences in 
medium-sized and large VLDL particles, that are rich in 
triglycerides, remain unclear and warrant further inves-
tigation; whereas intermediate-density lipoprotein and 
the smallest VLDL particles can penetrate the arterial 
wall to cause atherosclerosis, it is commonly perceived 
not be to the case for larger VLDL particles.38,48 We also 
observed a difference in lowering of VLDL cholesterol 
levels; the cholesterol concentrations of VLDL particles 
are strongly associated with risk of myocardial infarc-
tion,44 and some studies have suggested that VLDL cho-
lesterol could underpin the link between triglycerides 
and cardiovascular risk.38,41 If these VLDL particles do 
play a causal role in vascular disease, the discrepancy 
between statin therapy and PCSK9 inhibition could 
translate into slightly more potent cardiovascular risk 
reduction for the same LDL-C lowering for statins as 
compared with PCSK9 inhibition. We acknowledge that 
the present comparison of detailed metabolic effects of 
statin therapy and PCSK9 inhibition does not directly 
inform on the cardiovascular benefits of anti-PCSK9 
therapies above current optimal care, but potentially in 
keeping with our findings, the cardiovascular outcome 
trials on PCSK9 inhibition have demonstrated slightly 
weaker cardiovascular event lowering compared with 
meta-analysis of statin trials per mmol/L reduction in 
LDL-C.6 Although potential explanations for this dis-
crepancy include the short trial duration and choice of 
primary end point, other explanations, such as differ-
ences in anti-inflammatory effects, have also been sug-
gested.11,49 Our results provide an additional hypothesis 
for exploration: the apparent weaker cardioprotective 
effects of PCSK9 inhibitors compared with statins per 
unit reduction in LDL-C may be attributable to weaker 
reductions in VLDL lipid concentrations by PCSK9 inhi-
bition. This hypothesis warrants further investigation, 
including elucidation of the causal role of triglyceride-
rich VLDL particles in tandem with further examinations 
of the detailed lipid effect of PCSK9 inhibitors.
Strengths and limitations of our study warrant con-
sideration. The lack of NMR metabolomics data for a 
PCSK9 inhibition trial motivated the use of a loss-of-
function variant in PCSK9 as a proxy for the antici-
pated therapeutic effects. The close match in the de-
tailed metabolic effects of statin therapy and HMGCR 
observed in this study substantiates the validity of us-
ing genetic variants to mimic lipid-lowering effects in 
randomized trial settings. Although we note that the 
metabolic profile of other statins may differ from that 
of pravastatin, the similarity between HMGCR and 
statin therapy that we identified provides reassurances 
about the generalizability of our findings to other statin 
types. To robustly assess the metabolic effects of ge-
netic inhibition of PCSK9, we had >5 times the sam-
ple size of prior studies examining PCSK9 rs11591147 
on lipoprotein subclass profiles.14,15 Despite the large 
sample size, we had limited power to detect effects on 
glycolysis-related metabolites because of preanalytical 
effects causing depletion of glucose levels in the blood 
samples. Notwithstanding the increased risk for type 2 
diabetes mellitus linked with PCSK9 rs11591147-T, our 
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results indicating minute effects on glycolysis traits are 
in line with larger studies reporting null effects on fast-
ing glucose for this SNP. The divergency in VLDL lipid–
lowering effects between statins and genetic inhibition 
of PCSK9 could potentially be attributable to differ-
ences in the clinical characteristics of the older, high-
risk patients of the PROSPER trial in comparison with 
the younger cohort participants included in the genetic 
analyses. However, similar VLDL lowering effects at-
tributable to pravastatin as observed here in PROSPER 
were recently reported in PREVEND IT13 with younger 
and lower-risk trial participants (Figure I in the online-
only Data Supplement). The differences in VLDL effects 
were also recapitulated when directly comparing the ef-
fects of genetic inhibition of PCSK9 to that of HMGCR 
in the same study population (Figure IV in the online-
only Data Supplement), providing reassurance that the 
observed VLDL differences are primarily due to the mo-
lecular mechanisms. Furthermore, the scaling of results 
to the LDL-C lowering magnitude enables comparison 
of the metabolic effects regardless the possible differ-
ences in the absolute lipid levels between the study 
populations. A strength of the metabolomics platform 
used is the ability to profile lipoprotein subclasses and 
their lipid composition at high-throughput, however 
we acknowledge that other assays may provide even 
deeper characterization of lipid metabolism and non-
lipid pathways to further clarify the molecular effects of 
lipid-lowering therapies.50
In conclusion, we found highly similar metabolic ef-
fects of statin therapy and genetic inhibition of PCSK9 
across a comprehensive profile of lipids, lipoprotein 
subclasses, fatty acids, and polar metabolites. The 
detailed profiling of lipoprotein subclasses revealed 
weaker effects of PCSK9 inhibition on VLDL particles 
and their cholesterol concentrations in comparison with 
statins, when scaled to an equivalent lowering of LDL-
C. If some of these VLDL lipids have independent causal 
effects on cardiovascular risk, this could contribute to 
subtle differences in cardiovascular event reduction be-
tween statins and PCSK9 inhibitors. More broadly, these 
results exemplify the utility of large-scale metabolomics 
in combination with randomized trials and genetics to 
uncover potential molecular differences between re-
lated therapeutics.
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